Cargando…
Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
BACKGROUND: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. OBJECTIVE: The purpose of thi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403729/ https://www.ncbi.nlm.nih.gov/pubmed/36035406 http://dx.doi.org/10.3389/fmed.2022.900916 |
_version_ | 1784773443984556032 |
---|---|
author | Wang, Jiao Zhang, Shuo Xing, Meng Hong, Seokgyeong Liu, Liu Ding, Xiao-Jie Sun, Xiao-ying Luo, Ying Wang, Chun-xiao Zhang, Miao Li, Bin Li, Xin |
author_facet | Wang, Jiao Zhang, Shuo Xing, Meng Hong, Seokgyeong Liu, Liu Ding, Xiao-Jie Sun, Xiao-ying Luo, Ying Wang, Chun-xiao Zhang, Miao Li, Bin Li, Xin |
author_sort | Wang, Jiao |
collection | PubMed |
description | BACKGROUND: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. OBJECTIVE: The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis. METHODS: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis. RESULTS: The study included eight randomized controlled studies, four single-arm studies, and four in vitro studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): −0.94; 95% CI: [−1.58, −0.31]; p = 0.004]. Oral statins performed best at week eight (SMD: −0.92; 95% CI: [−1.39, −0.44]; p = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20–CCR6 interaction, and reduction in the levels of inflammatory factors. LIMITATIONS: There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing. CONCLUSION: The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects. |
format | Online Article Text |
id | pubmed-9403729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94037292022-08-26 Current evidence on the role of lipid lowering drugs in the treatment of psoriasis Wang, Jiao Zhang, Shuo Xing, Meng Hong, Seokgyeong Liu, Liu Ding, Xiao-Jie Sun, Xiao-ying Luo, Ying Wang, Chun-xiao Zhang, Miao Li, Bin Li, Xin Front Med (Lausanne) Medicine BACKGROUND: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. OBJECTIVE: The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis. METHODS: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis. RESULTS: The study included eight randomized controlled studies, four single-arm studies, and four in vitro studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): −0.94; 95% CI: [−1.58, −0.31]; p = 0.004]. Oral statins performed best at week eight (SMD: −0.92; 95% CI: [−1.39, −0.44]; p = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20–CCR6 interaction, and reduction in the levels of inflammatory factors. LIMITATIONS: There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing. CONCLUSION: The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403729/ /pubmed/36035406 http://dx.doi.org/10.3389/fmed.2022.900916 Text en Copyright © 2022 Wang, Zhang, Xing, Hong, Liu, Ding, Sun, Luo, Wang, Zhang, Li and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Wang, Jiao Zhang, Shuo Xing, Meng Hong, Seokgyeong Liu, Liu Ding, Xiao-Jie Sun, Xiao-ying Luo, Ying Wang, Chun-xiao Zhang, Miao Li, Bin Li, Xin Current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
title | Current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
title_full | Current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
title_fullStr | Current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
title_full_unstemmed | Current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
title_short | Current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
title_sort | current evidence on the role of lipid lowering drugs in the treatment of psoriasis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403729/ https://www.ncbi.nlm.nih.gov/pubmed/36035406 http://dx.doi.org/10.3389/fmed.2022.900916 |
work_keys_str_mv | AT wangjiao currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT zhangshuo currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT xingmeng currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT hongseokgyeong currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT liuliu currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT dingxiaojie currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT sunxiaoying currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT luoying currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT wangchunxiao currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT zhangmiao currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT libin currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis AT lixin currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis |